Investigating quality of life in those with large B-cell lymphoma

Digital transformation conceptual for next generation technology era

Patient-reported outcomes from individuals diagnosed with relapsed or refractory large B-cell lymphoma revealed that those who received axicabtagene ciloleucel (axi-cel) immunotherapy experienced higher quality of life than those who received standard care, according to findings published in Blood.

Understanding brief resolved unexplained events in infants

Previous article

COVID-19 drug trial results released

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations